JP2014519524A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014519524A5 JP2014519524A5 JP2014515918A JP2014515918A JP2014519524A5 JP 2014519524 A5 JP2014519524 A5 JP 2014519524A5 JP 2014515918 A JP2014515918 A JP 2014515918A JP 2014515918 A JP2014515918 A JP 2014515918A JP 2014519524 A5 JP2014519524 A5 JP 2014519524A5
- Authority
- JP
- Japan
- Prior art keywords
- monoclonal antibody
- seq
- heavy chain
- amino acid
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 201000004681 Psoriasis Diseases 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 108010054395 P-selectin ligand protein Proteins 0.000 claims 4
- 238000002054 transplantation Methods 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010037575 Pustular psoriasis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 238000010322 bone marrow transplantation Methods 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 230000001185 psoriatic effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161496249P | 2011-06-13 | 2011-06-13 | |
| US61/496,249 | 2011-06-13 | ||
| PCT/US2012/042068 WO2012174001A1 (en) | 2011-06-13 | 2012-06-12 | Anti-psgl-1 antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014519524A JP2014519524A (ja) | 2014-08-14 |
| JP2014519524A5 true JP2014519524A5 (enExample) | 2015-07-30 |
| JP6180408B2 JP6180408B2 (ja) | 2017-08-16 |
Family
ID=47357432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014515918A Active JP6180408B2 (ja) | 2011-06-13 | 2012-06-12 | 抗ｐｓｇｌ−１抗体およびその使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20130209449A9 (enExample) |
| EP (2) | EP3925978A1 (enExample) |
| JP (1) | JP6180408B2 (enExample) |
| KR (1) | KR102103036B1 (enExample) |
| CN (3) | CN116063522A (enExample) |
| AU (1) | AU2012271845B2 (enExample) |
| BR (1) | BR112013031892A2 (enExample) |
| CA (1) | CA2838952C (enExample) |
| CL (1) | CL2013003570A1 (enExample) |
| CO (1) | CO6940376A2 (enExample) |
| EC (1) | ECSP14013132A (enExample) |
| IL (2) | IL229844B (enExample) |
| MX (1) | MX358447B (enExample) |
| NZ (1) | NZ619524A (enExample) |
| PH (1) | PH12013502568B1 (enExample) |
| RU (1) | RU2650817C2 (enExample) |
| SG (1) | SG10201604767TA (enExample) |
| TW (1) | TWI643872B (enExample) |
| UA (1) | UA114712C2 (enExample) |
| WO (1) | WO2012174001A1 (enExample) |
| ZA (1) | ZA201400209B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7744888B2 (en) | 2001-08-03 | 2010-06-29 | Abgenomics Cooperatief U.A. | Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies |
| US20040116333A1 (en) | 2001-08-03 | 2004-06-17 | Rong-Hwa Lin | Modulators of P-selectin glycoprotein ligand 1 |
| UY28886A1 (es) | 2004-05-10 | 2005-12-30 | Boehringer Ingelheim Int | Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18 |
| BRPI0510561A (pt) | 2004-05-11 | 2007-11-20 | Abgenomics Corp | epìtopos que induzem morte de célula t |
| CN116063522A (zh) | 2011-06-13 | 2023-05-05 | 美国全心医药生技股份有限公司 | 抗psgl-1抗体及其用途 |
| EP3881863A1 (en) * | 2014-07-08 | 2021-09-22 | Sanford-Burnham Medical Research Institute | Psgl-1 modulators and uses thereof |
| ES2880731T3 (es) * | 2016-01-08 | 2021-11-25 | Altrubio Inc | Anticuerpos anti-PSGL-1 tetravalentes y usos de los mismos |
| WO2017214941A1 (zh) * | 2016-06-16 | 2017-12-21 | 毛侃琅 | 一种提升SelP基因表达水平的慢病毒载体及其应用 |
| JP7244422B2 (ja) | 2017-01-11 | 2023-03-22 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐｓｇｌ－１アンタゴニスト及びその使用 |
| TW202506185A (zh) | 2017-01-20 | 2025-02-16 | 法商賽諾菲公司 | 抗TGF-β抗體及其用途 |
| AR110755A1 (es) | 2017-01-20 | 2019-05-02 | Genzyme Corp | Anticuerpos dirigidos a hueso |
| SG11201907848YA (en) | 2017-03-14 | 2019-09-27 | Five Prime Therapeutics Inc | Antibodies binding to vista at acidic ph |
| MX2020009786A (es) | 2018-03-21 | 2020-10-12 | Five Prime Therapeutics Inc | Anticuerpos de union a supresor de la activacion de celulas t que contiene el dominio variable de inmunoglobulina (vista) a ph acido. |
| US12091462B2 (en) | 2018-07-11 | 2024-09-17 | Five Prime Therapeutics, Inc. | Antibodies binding to vista at acidic pH |
| CN118994395A (zh) | 2018-07-20 | 2024-11-22 | 皮埃尔法布雷医药公司 | Vista受体 |
| TW202110891A (zh) * | 2019-06-04 | 2021-03-16 | 美商維西歐製藥公司 | 抗psgl-1組合物及其用於調節骨髓細胞發炎表型之方法及用途 |
| CN115803091A (zh) * | 2020-05-22 | 2023-03-14 | 福迈康股份公司 | Ace2-fc融合蛋白及其用途 |
| CN113667015B (zh) * | 2021-08-20 | 2022-10-11 | 北京康特泊瑞生物医药科技股份公司 | 靶向psgl-1蛋白的抗体及其用途 |
| JP2024540484A (ja) * | 2021-11-17 | 2024-10-31 | アルトゥルバイオ， インコーポレイテッド | 抗ｐｓｇｌ－１抗体をｊａｋ阻害剤と組み合わせて使用してｔ細胞媒介性炎症性疾患またはがんを治療する方法 |
| CN120265323A (zh) * | 2022-09-13 | 2025-07-04 | 泰克斯制药公司 | 抗体、组合物和治疗方法 |
| WO2025106784A1 (en) * | 2023-11-17 | 2025-05-22 | Altrubio Inc. | Anti-psgl-1 antibodies and uses thereof |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5464778A (en) | 1989-03-08 | 1995-11-07 | Board Of Regents Of The University Of Oklahoma | Glycoprotein ligand for P-selectin and methods of use thereof |
| US5378464A (en) | 1989-03-08 | 1995-01-03 | Board Of Regents Of The University Of Oklahoma | Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140 |
| US5690933A (en) | 1989-05-31 | 1997-11-25 | Glaxo Wellcome Inc. | Monoclonal antibodies for inducing tolerance |
| US5709859A (en) | 1991-01-24 | 1998-01-20 | Bristol-Myers Squibb Company | Mixed specificity fusion proteins |
| US6309639B1 (en) | 1991-02-05 | 2001-10-30 | The Board Of Regents Of The University Of Oklahoma | Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand |
| US6124267A (en) | 1991-02-05 | 2000-09-26 | Southpac Trust Internationals, Inc. | O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1 |
| US5972625A (en) | 1991-05-06 | 1999-10-26 | The Regents Of The University Of California | Assays for inhibitors of leukocyte adhesion |
| ES2131107T3 (es) | 1992-03-17 | 1999-07-16 | Novartis Ag | Anticuerpos obtenidos mediante ingenieria genetica. |
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| US5843707A (en) | 1992-10-23 | 1998-12-01 | Genetics Institute, Inc. | Nucleic acid encoding a novel P-selectin ligand protein |
| US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
| WO1994014836A1 (en) | 1992-12-18 | 1994-07-07 | Centocor, Inc. | Peptide inhibitors of selectin binding |
| ES2126742T3 (es) | 1993-01-25 | 1999-04-01 | Dana Farber Cancer Inst Inc | Selectinas quimericas obtenidas mediante intercambio de dominios - sus usos. |
| WO1995014787A1 (en) | 1993-11-22 | 1995-06-01 | Centocor, Inc. | Peptide inhibitors of selecting binding |
| FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
| ES2208759T3 (es) | 1995-08-03 | 2004-06-16 | Board Of Regents Of The University Of Oklahoma | O-glicanos inhibidores de la inflamacion mediada por selectina. |
| US6348581B1 (en) | 1996-10-31 | 2002-02-19 | The Dow Chemical Company | High affinity humanized anti-TAG-72 monoclonalantibodies |
| WO1999043353A2 (en) | 1998-02-26 | 1999-09-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | Combination anti-selectin and immunosuppressant therapy |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| NZ528610A (en) | 1998-10-30 | 2005-03-24 | Inst Genetics Llc | Inhibition of differentiation of cytotoxic T-cells by P-selectin ligand (PSGL) antagonists |
| CA2369292C (en) | 1999-04-09 | 2010-09-21 | Kyowa Hakko Kogyo Co. Ltd. | Method of modulating the activity of functional immune molecules |
| US6696620B2 (en) | 2000-05-02 | 2004-02-24 | Epicyte Pharmaceutical, Inc. | Immunoglobulin binding protein arrays in eukaryotic cells |
| US20020031508A1 (en) | 2000-05-19 | 2002-03-14 | Wagner Denisa D. | Methods for diagnosing and treating hemostatic disorders by modulating P-selectin activity |
| AU2000274809A1 (en) | 2000-09-12 | 2002-03-26 | Genetics Institute Llc | Inhibition of stenosis or restenosis by p-selectin antagonists |
| US20040002450A1 (en) | 2000-12-29 | 2004-01-01 | Janette Lazarovits | Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| US20040001839A1 (en) | 2000-12-29 | 2004-01-01 | Avigdor Levanon | Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| JP2005503756A (ja) | 2000-12-29 | 2005-02-10 | サビエント ファーマシューティカルズ，インコーポレイティド | 硫酸化部分を含むエピトープを含む単離分子、当該エピトープに対する抗体、及びその使用 |
| CA2868614A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| US6884619B2 (en) | 2001-07-17 | 2005-04-26 | Yale University | Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors |
| US7744888B2 (en) | 2001-08-03 | 2010-06-29 | Abgenomics Cooperatief U.A. | Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies |
| US20040116333A1 (en) | 2001-08-03 | 2004-06-17 | Rong-Hwa Lin | Modulators of P-selectin glycoprotein ligand 1 |
| ATE430580T1 (de) | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| RU2005101621A (ru) | 2002-07-01 | 2005-11-20 | Савиент Фармасьютикалс, Инк. (Us) | Антитела и их применения |
| US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
| EP1646401A4 (en) | 2003-06-30 | 2007-07-18 | Bio Technology General Israel | SPECIFIC HUMAN ANTIBODIES |
| RU2377254C2 (ru) * | 2003-12-25 | 2009-12-27 | Кирин Фарма Кабусики Кайся | Мутанты анти-cd40 антитела |
| AU2005214361B2 (en) * | 2004-02-13 | 2011-03-24 | Immunomedics, Inc. | Fusion proteins containing recombinant cytotoxic RNAses |
| BR122019012028B1 (pt) * | 2004-04-13 | 2023-09-26 | F. Hoffmann-La Roche Ag | Anticorpos anti-p-selectina, molécula de ácido nucléico, vetor, e composição |
| UY28886A1 (es) | 2004-05-10 | 2005-12-30 | Boehringer Ingelheim Int | Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18 |
| BRPI0510561A (pt) | 2004-05-11 | 2007-11-20 | Abgenomics Corp | epìtopos que induzem morte de célula t |
| US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| TWI380996B (zh) * | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| TWI461436B (zh) * | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法 |
| TWI551607B (zh) * | 2006-07-14 | 2016-10-01 | Ａｃ免疫公司 | 人類化抗體 |
| HRP20140661T1 (hr) * | 2007-03-22 | 2014-10-10 | Genentech, Inc. | Apoptotiäśka protutijela anti-ige koja vežu ige spojen s membranom |
| AU2008234248C1 (en) * | 2007-03-29 | 2015-01-22 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| WO2008145142A1 (en) * | 2007-05-31 | 2008-12-04 | Genmab A/S | Stable igg4 antibodies |
| EP2155238B1 (en) | 2007-06-05 | 2016-04-06 | Yale University | Antibody against d4 domain of the kit receptor and use thereor |
| CN101842117A (zh) | 2007-08-28 | 2010-09-22 | 比奥根艾迪克Ma公司 | 抗igf-1r抗体及其用途 |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| US8092804B2 (en) * | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| US20110086366A1 (en) * | 2008-02-22 | 2011-04-14 | Genmab A/S | Methods for assessing the risk of adverse events upon treatment with igg4 antibodies |
| AU2009246166B2 (en) * | 2008-05-15 | 2014-09-18 | Tetherex Pharmaceuticals Corporation | Anti-PSGL-1 antibodies and methods of identification and use |
| KR20110128923A (ko) * | 2009-03-12 | 2011-11-30 | 이메드 아베 | 인간 ｆａｓ에 대한 인간 항체 및 그의 용도 |
| EP2459594A1 (en) | 2009-07-31 | 2012-06-06 | N.V. Organon | Fully human antibodies to btla |
| CN116063522A (zh) | 2011-06-13 | 2023-05-05 | 美国全心医药生技股份有限公司 | 抗psgl-1抗体及其用途 |
| CN106659783A (zh) | 2014-06-20 | 2017-05-10 | 艾比吉诺米克斯国际股份有限公司 | Her2抗体‑药物缀合物 |
-
2012
- 2012-06-12 CN CN202211394154.4A patent/CN116063522A/zh active Pending
- 2012-06-12 RU RU2013158083A patent/RU2650817C2/ru active
- 2012-06-12 CA CA2838952A patent/CA2838952C/en active Active
- 2012-06-12 EP EP21168455.0A patent/EP3925978A1/en active Pending
- 2012-06-12 KR KR1020147000603A patent/KR102103036B1/ko active Active
- 2012-06-12 WO PCT/US2012/042068 patent/WO2012174001A1/en not_active Ceased
- 2012-06-12 SG SG10201604767TA patent/SG10201604767TA/en unknown
- 2012-06-12 JP JP2014515918A patent/JP6180408B2/ja active Active
- 2012-06-12 PH PH1/2013/502568A patent/PH12013502568B1/en unknown
- 2012-06-12 UA UAA201314798A patent/UA114712C2/uk unknown
- 2012-06-12 AU AU2012271845A patent/AU2012271845B2/en active Active
- 2012-06-12 CN CN201280039482.0A patent/CN103732626A/zh active Pending
- 2012-06-12 NZ NZ619524A patent/NZ619524A/en unknown
- 2012-06-12 CN CN201810722769.2A patent/CN108892726A/zh active Pending
- 2012-06-12 EP EP12799966.2A patent/EP2718325A4/en not_active Ceased
- 2012-06-12 MX MX2013014814A patent/MX358447B/es active IP Right Grant
- 2012-06-12 BR BR112013031892A patent/BR112013031892A2/pt not_active Application Discontinuation
- 2012-06-12 US US13/494,398 patent/US20130209449A9/en not_active Abandoned
- 2012-06-13 TW TW101121146A patent/TWI643872B/zh active
-
2013
- 2013-04-17 US US13/865,085 patent/US20130251708A1/en not_active Abandoned
- 2013-12-08 IL IL229844A patent/IL229844B/en unknown
- 2013-12-12 CL CL2013003570A patent/CL2013003570A1/es unknown
-
2014
- 2014-01-09 ZA ZA2014/00209A patent/ZA201400209B/en unknown
- 2014-01-13 CO CO14004726A patent/CO6940376A2/es unknown
- 2014-01-13 EC ECSP14013132 patent/ECSP14013132A/es unknown
-
2021
- 2021-08-30 US US17/460,883 patent/US11897964B2/en active Active
- 2021-10-14 IL IL287270A patent/IL287270A/en unknown
-
2023
- 2023-12-26 US US18/396,607 patent/US20240124604A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014519524A5 (enExample) | ||
| RU2013158083A (ru) | Анти-psgl-1-антитела и их применение | |
| JP2014505463A5 (enExample) | ||
| HRP20220811T1 (hr) | Agonistička sredstva za vezanje tnf receptora | |
| FR22C1052I1 (fr) | Anticorps anti-cd19 humanises et leur utilisation dans le traitement des tumeurs, de la transplantation et des maladies auto-immunes | |
| RU2012139181A (ru) | Стабильная композиция, содержащая антитело | |
| RU2571204C3 (ru) | Специфические связывающие агенты против в7-н1 | |
| RU2019119442A (ru) | Новый коньюгат аманитина | |
| RU2016151265A (ru) | Антитела, направленные на cd127 | |
| JP2010500370A5 (enExample) | ||
| JP2013545438A5 (enExample) | ||
| JP2012070740A5 (enExample) | ||
| EP2543727A4 (en) | MODIFIED ANTIBODY COMPOSITION | |
| SI2753646T1 (en) | Anti-CD40 antibodies, uses and methods | |
| CO2017011486A2 (es) | Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales | |
| JP2010526028A5 (enExample) | ||
| SI2771031T1 (en) | Humanized antibodies that recognize alpha-synuclein | |
| JP2015535828A5 (enExample) | ||
| RU2017102193A (ru) | Конструкции полиспецифических антител | |
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| SI2542257T1 (en) | Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI) | |
| JP2015514090A5 (enExample) | ||
| RU2016129894A (ru) | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения | |
| CA2813849C (en) | Secukinumab for use in the treatment of ankylosing spondylitis | |
| JP2008527989A5 (enExample) |